These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 28335769)

  • 21. Performance of cryptococcal antigen lateral flow assay in serum, cerebrospinal fluid, whole blood, and urine in HIV-infected patients with culture-proven cryptococcal meningitis admitted at a Brazilian referral center.
    Vidal JE; Toniolo C; Paulino A; Colombo AL; Martins MDA; Meira CDS; Azevedo RGS; Pereira-Chioccola VL; Gomes HR; Lazera MDS; Oliveira ACP; Boulware DR
    Rev Inst Med Trop Sao Paulo; 2018; 60():e1. PubMed ID: 29451598
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of screening and treatment of cryptococcal antigenaemia among HIV-infected persons in Soweto, South Africa.
    Govender NP; Roy M; Mendes JF; Zulu TG; Chiller TM; Karstaedt AS
    HIV Med; 2015 Sep; 16(8):468-76. PubMed ID: 25689352
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A qualitative evaluation of an implementation study for cryptococcal antigen screening and treatment in Uganda.
    Lofgren SM; Nalintya E; Meya DB; Boulware DR; Rajasingham R
    Medicine (Baltimore); 2018 Aug; 97(31):e11722. PubMed ID: 30075580
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Prospective Evaluation of a Multisite Cryptococcal Screening and Treatment Program in HIV Clinics in Uganda.
    Nalintya E; Meya DB; Lofgren S; Huppler Hullsiek K; Boulware DR; Rajasingham R
    J Acquir Immune Defic Syndr; 2018 Jun; 78(2):231-238. PubMed ID: 29509588
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevalence, correlates, and outcomes of cryptococcal antigen positivity among patients with AIDS, United States, 1986-2012.
    McKenney J; Bauman S; Neary B; Detels R; French A; Margolick J; Doherty B; Klausner JD
    Clin Infect Dis; 2015 Mar; 60(6):959-65. PubMed ID: 25422390
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness of single-dose AmBisome pre-emptive treatment for the prevention of cryptococcal meningitis in African low and middle-income countries.
    Rajasingham R; Nalintya E; Israelski DM; Meya DB; Larson BA; Boulware DR
    Med Mycol; 2022 Feb; 60(2):. PubMed ID: 35026017
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The prevalence of cryptococcal antigen (CrAg) and benefits of pre-emptive antifungal treatment among HIV-infected persons with CD4+ T-cell counts < 200 cells/μL: evidence based on a meta-analysis.
    Li Y; Huang X; Chen H; Qin Y; Hou J; Li A; Wu H; Yan X; Chen Y
    BMC Infect Dis; 2020 Jun; 20(1):410. PubMed ID: 32532212
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cryptococcal Meningitis Diagnostics and Screening in the Era of Point-of-Care Laboratory Testing.
    Rajasingham R; Wake RM; Beyene T; Katende A; Letang E; Boulware DR
    J Clin Microbiol; 2019 Jan; 57(1):. PubMed ID: 30257903
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Establishing a cost-per-result of laboratory-based, reflex Cryptococcal antigenaemia screening (CrAg) in HIV+ patients with CD4 counts less than 100 cells/μl using a Lateral Flow Assay (LFA) at a typical busy CD4 laboratory in South Africa.
    Cassim N; Schnippel K; Coetzee LM; Glencross DK
    PLoS One; 2017; 12(2):e0171675. PubMed ID: 28166254
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prospective cohort of AIDS patients screened for cryptococcal antigenaemia, pre-emptively treated and followed in Brazil.
    Borges MASB; de Araújo Filho JA; Oliveira BJS; Moreira IS; de Paula VV; de Bastos AL; Soares RBA; Turchi MD
    PLoS One; 2019; 14(7):e0219928. PubMed ID: 31344140
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Laboratory Reflex and Clinic-Based Point-of-Care Cryptococcal Antigen Screening for Preventing Meningitis and Mortality Among People Living With HIV.
    Drain PK; Galagan SR; Govere S; Krows M; Thulare H; Wallis CL; Gosnell BI; Moosa MY; Celum C; Bassett IV
    J Acquir Immune Defic Syndr; 2021 Aug; 87(5):1205-1213. PubMed ID: 33990495
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multisite validation of cryptococcal antigen lateral flow assay and quantification by laser thermal contrast.
    Boulware DR; Rolfes MA; Rajasingham R; von Hohenberg M; Qin Z; Taseera K; Schutz C; Kwizera R; Butler EK; Meintjes G; Muzoora C; Bischof JC; Meya DB
    Emerg Infect Dis; 2014 Jan; 20(1):45-53. PubMed ID: 24378231
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Symptomatic Cryptococcal Antigenemia Presenting as Early Cryptococcal Meningitis With Negative Cerebral Spinal Fluid Analysis.
    Ssebambulidde K; Bangdiwala AS; Kwizera R; Kandole TK; Tugume L; Kiggundu R; Mpoza E; Nuwagira E; Williams DA; Lofgren SM; Abassi M; Musubire AK; Cresswell FV; Rhein J; Muzoora C; Hullsiek KH; Boulware DR; Meya DB;
    Clin Infect Dis; 2019 May; 68(12):2094-2098. PubMed ID: 30256903
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Screening HIV-Infected Patients with Low CD4 Counts for Cryptococcal Antigenemia prior to Initiation of Antiretroviral Therapy: Cost Effectiveness of Alternative Screening Strategies in South Africa.
    Larson BA; Rockers PC; Bonawitz R; Sriruttan C; Glencross DK; Cassim N; Coetzee LM; Greene GS; Chiller TM; Vallabhaneni S; Long L; van Rensburg C; Govender NP
    PLoS One; 2016; 11(7):e0158986. PubMed ID: 27390864
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Laboratory-Reflex Cryptococcal Antigen Screening Is Associated With a Survival Benefit in Tanzania.
    Faini D; Kalinjuma AV; Katende A; Mbwaji G; Mnzava D; Nyuri A; Glass TR; Furrer H; Hatz C; Boulware DR; Letang E
    J Acquir Immune Defic Syndr; 2019 Feb; 80(2):205-213. PubMed ID: 30422904
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High Cryptococcal Antigen Titers in Blood Are Predictive of Subclinical Cryptococcal Meningitis Among Human Immunodeficiency Virus-Infected Patients.
    Wake RM; Britz E; Sriruttan C; Rukasha I; Omar T; Spencer DC; Nel JS; Mashamaite S; Adelekan A; Chiller TM; Jarvis JN; Harrison TS; Govender NP
    Clin Infect Dis; 2018 Feb; 66(5):686-692. PubMed ID: 29028998
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Point-of-Care Testing for Cryptococcal Disease Among Hospitalized Human Immunodeficiency Virus-Infected Adults in Ethiopia.
    Mamuye AT; Bornstein E; Temesgen O; Blumberg HM; Kempker RR
    Am J Trop Med Hyg; 2016 Oct; 95(4):786-792. PubMed ID: 27527636
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness of reflex laboratory-based cryptococcal antigen screening for the prevention and treatment of cryptococcal meningitis in Botswana.
    Tenforde MW; Muthoga C; Callaghan A; Ponatshego P; Ngidi J; Mine M; Jordan A; Chiller T; Larson BA; Jarvis JN
    Wellcome Open Res; 2019; 4():144. PubMed ID: 31803848
    [No Abstract]   [Full Text] [Related]  

  • 39. Prevalence and mortality of cryptococcal disease in adults with advanced HIV in an urban tertiary hospital in Sierra Leone: a prospective study.
    Lakoh S; Rickman H; Sesay M; Kenneh S; Burke R; Baldeh M; Jiba DF; Tejan YS; Boyle S; Koroma C; Deen GF; Beynon F
    BMC Infect Dis; 2020 Feb; 20(1):141. PubMed ID: 32059703
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence of cryptococcal infection among advanced HIV patients in Argentina using lateral flow immunoassay.
    Frola C; Guelfand L; Blugerman G; Szyld E; Kaufman S; Cahn P; Sued O; Pérez H
    PLoS One; 2017; 12(6):e0178721. PubMed ID: 28617817
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.